Breath powered™ nasal delivery of 22 mg sumatriptan powder (AVP-825): An exploratory analysis of response in migraine patients grouped by baseline headache intensity from the phase 3 target study

The requested reference [87702c0c442157f91752a2d2aea18f51de4da4aa] no longer exists in our database. It has been replaced by the current reference: [9e495dab46c7013708c88b2723ea1098ed48fb74]

Authors
Category Primary study
JournalNeurology
Year 2015
This article has no abstract
Epistemonikos ID: 31606fbac445665ed37b7dfb52cdd4710c1da0d8
First added on: Feb 07, 2025